Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2008, p. 3534-3536, Vol. 46, No. 10
0095-1137/08/$08.00+0 doi:10.1128/JCM.00989-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
| CASE REPORT |

University of South Alabama, Department of Pathology, Mobile, Alabama
Received 22 May 2008/ Returned for modification 15 July 2008/ Accepted 21 July 2008
|
|
|---|
|
|
|---|
![]() View larger version (40K): [in a new window] |
FIG. 1. Computed tomography scan of the chest showing an 8.1- by 6.5-cm lesion which extends from the left upper lobe of the lung into the extrathoracic soft tissues beneath the left upper pectoralis muscle.
|
![]() View larger version (174K): [in a new window] |
FIG. 2. Lung tissue showing inflammation and fibroblast proliferation predominately involving bronchial lumens and peribronchial air spaces, consistent with an organized pneumonia-like pattern. (Stained with hematoxylin and eosin.) Magnification, x20.
|
A rare complication of empyema in which the pleural infection spreads outside of the pleural space to involve the soft tissues of the chest wall is known as empyema necessitatis. The most common location of an extension is the anterior chest wall between the midclavicular and anterior axillary lines (3). Other reported locations of extensions include the abdominal wall, paravertebral space, vertebrae, esophagus, bronchus, mediastinum, diaphragm, pericardium, flank, breast, and retroperitoneum (5, 7).
First described in the medical literature by Gullan De Baillon in 1640, empyema necessitatis is an uncommon complication of empyema in which inflammation associated with an underlying pulmonary bacterial infection bridges the pleural space and involves the thoracic wall. The first modern review of this entity was a description of 115 cases by Sindel in 1940, but due to the advent of antibiotic therapy since that time, the incidence of empyema necessitatis has declined significantly (6). The majority of empyema necessitatis cases are caused by Mycobacterium tuberculosis, although many other organisms have also been implicated, including S. aureus. Only two previous cases of MRSA empyema necessitatis have been reported in the medical literature.
Empyema necessitatis may be asymptomatic but can also present vaguely as pleuritic chest pain and a nonproductive cough. Most commonly, an enlarging soft tissue mass is present on the chest wall (5). As in the current case, computerized tomography is necessary to make the diagnosis. A computerized tomography scan demonstrates a pleural effusion connected to the chest wall mass, which is pathognomonic for empyema necessitatis (5).
For the clinician, the differential diagnosis of an empyema with chest wall extension includes lymphomas, primary pulmonary neoplasms such as bronchogenic carcinoma and mesothelioma, sarcomas, and, finally, infective endocarditis with septic embolization (8). The clinical presentation can be helpful in making the diagnosis of empyema necessitatis. Neoplasms typically have a more indolent presentation and generalized symptoms. Lymphadenopathy is usually present in patients with lymphomas.
The median age at diagnosis of empyema necessitatis is 44.5 years, with a range of 3 months to 81 years (1, 3). It is extremely rare in pediatric patients. The first pediatric case was reported by Laennec in a 12-year-old male (3). The youngest patient reported in the medical literature was a 3-month-old female with empyema necessitatis caused by MRSA.
Since the introduction of antibiotics, the number of cases of empyema necessitatis has decreased significantly (8). M. tuberculosis remains the most common etiologic agent, but Actinomyces species have replaced Streptococcus pneumoniae as the second most common cause (7, 8). Less common etiologic agents include S. aureus, Streptococcus milleri, Fusobacterium nucleatum, Mycobacterium avium, Mycobacterium intracellulare, Burkholderia cepacia, and Blastomyces spp. (7). Interestingly, Pseudomonas cepacia has been reported as a cause of empyema necessitatis in patients with cystic fibrosis following lung transplantation (4).
Only rare cases of empyema necessitatis due to MRSA have been reported in the medical literature. In 2005, the first reported case of MRSA-related empyema necessitatis was diagnosed in an 8-month-old male (7). The patient was treated with surgical drainage and a 10-day course of vancomycin followed by oral trimethoprim-sulfamethoxazole to complete a 21-day course. A second case of MRSA-related empyema necessitatis, in a 3-month-old female, was reported in 2006 (3). The patient was treated with thoracotomy with decortication and tube thoracostomy and a 14-day course of vancomycin followed by oral linezolid for 7 days. To our knowledge, our case represents only the third reported case of MRSA-related empyema necessitatis and the only case occurring in an adult.
The treatment of empyema necessitatis includes surgical drainage and antimicrobial therapy (2). The overall mortality rate in the preantibiotic era was 66%, with a mortality rate of 87% in cases of M. tuberculosis-related empyema necessitatis and 28% in cases of S. pneumoniae-related empyema necessitatis (1). Since the advent of antimicrobial therapy, no fatalities have been documented. In the treatment of empyema necessitatis, prophylactic antibiotic coverage for possible pathogens should begin immediately after diagnosis, and antimicrobial therapy can subsequently be altered when the susceptibility patterns of the cultured organism are available. Empyema necessitatis caused by M. tuberculosis has a cure rate of 99% when treated with 9 to 12 months of isoniazid and rifampin (5). Antimicrobial agents that have been reported as efficacious in the treatment of the rare cases of documented MRSA-related empyema necessitatis include vancomycin, linezolid, trimethoprim-sulfamethoxazole, and rifampin (3).
In summary, our case represents an extremely rare manifestation of an increasingly dangerous bacterial pathogen. Empyema necessitatis should be suspected in any patient with pulmonary symptoms presenting with a chest wall mass as well as in patients with known skin and soft tissue infections of the chest wall. Imaging studies and sampling of the lesions by aspiration or biopsy are the mainstays of diagnosis. Appropriate antimicrobial therapy and surgical drainage of the empyema are the mainstays to a successful outcome in cases of empyema necessitatis.
Published ahead of print on 30 July 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»